| Bioactivity | Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment[1]. | |||||||||
| Name | Tedalinab | |||||||||
| CAS | 916591-01-0 | |||||||||
| Formula | C19H21F2N3O | |||||||||
| Molar Mass | 345.39 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Glenmark’s molecule for neuropathic pain, osteoarthritis - GRC 10693, successfully completes Phase I trials. |
Tedalinab
CAS: 916591-01-0 F: C19H21F2N3O W: 345.39
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >470
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.